Cancer NetworkOriginal article
<![CDATA[Personalized Cancer Vaccine Combo Is Feasible in Platinum-Sensitive Ovarian Cancer]]>
Phase 1positivepersonalized neoantigen vaccinenivolumabPositive
AI Analysis
Summary
A phase 1 trial demonstrated that a personalized neoantigen vaccine combined with nivolumab is feasible and shows no unexpected safety signals in patients with platinum-sensitive high-grade ovarian cancer.
Clinical Trial Data
Phase
1
Outcome Details
No unexpected safety signals observed with personalized neoantigen vaccine plus nivolumab combination
Importance:5/10
Sentiment:
0.60
oncologyovarian cancerimmunotherapyneoantigen vaccinecombination therapysafety
Read the original article
Published by Cancer Network on October 15, 2026 4:00 PM